Lifestyle intervention and/or statins for the reduction of C‐reactive protein in type 2 diabetes: From the look AHEAD study
Objective: Cardiovascular risk remains high despite statin use. Overweight/obese diabetic persons usually have normal/low LDL‐cholesterol but high C‐reactive protein (CRP) levels. We aimed to examine the effects of intensive lifestyle intervention for weight loss (ILI) on CRP levels in overweight/ob...
Gespeichert in:
| Veröffentlicht in: | Obesity (Silver Spring, Md.) Md.), 2013-05, Vol.21 (5), p.944-950 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 950 |
|---|---|
| container_issue | 5 |
| container_start_page | 944 |
| container_title | Obesity (Silver Spring, Md.) |
| container_volume | 21 |
| creator | Belalcazar, L. Maria Haffner, Steven M. Lang, Wei Hoogeveen, Ron C. Rushing, Julia Schwenke, Dawn C. Tracy, Russell P. Pi‐Sunyer, F. Xavier Kriska, Andrea M. Ballantyne and the Look AHEAD (Action for Health in Diabetes) Research Group, Christie M. |
| description | Objective:
Cardiovascular risk remains high despite statin use. Overweight/obese diabetic persons usually have normal/low LDL‐cholesterol but high C‐reactive protein (CRP) levels. We aimed to examine the effects of intensive lifestyle intervention for weight loss (ILI) on CRP levels in overweight/obese diabetic individuals by statin use.
Design and Methods:
Look AHEAD was a randomized trial in overweight/obese type 2 diabetic individuals testing whether ILI would reduce cardiovascular mortality, when compared to usual care. CRP changes in 1,431 participants with biomarker levels, who remained on or off statin treatment for 1 year, were evaluated.
Results:
The reduction in CRP levels with ILI at 1 year in men and women on statins was −44.9 and −42.3%, respectively, compared to −13.7 and −21.0% for those on statins and usual care (P < 0.0001). At 1 year, median CRP levels were: 1.8 mg L−1 in participants randomized to ILI on statin therapy; 2.6 mg L−1 for those on statins randomized to usual care and 2.9 mg L−1 for participants not on statins but randomized to ILI. Weight loss was associated with 1‐year CRP reduction (P < 0.0001) in statin and nonstatin users.
Conclusions:
Our findings suggest that in overweight/obese diabetic persons, ILI and statin therapy may have substantial additive anti‐inflammatory benefits. |
| doi_str_mv | 10.1002/oby.20431 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3689862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3661780501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5091-255d7332cff1213365f56d5457088f402ac7d4cf8c187fc5be5889242c79d0fe3</originalsourceid><addsrcrecordid>eNp1kctuEzEUhkcIREthwQsgS2xgkcaX8WVYIKWhpZUidQMSrCzHPqYuk3Fqz6SaBRKPwDPyJJikRAWJlY91Pn86x39VPSf4mGBMp3E5HlNcM_KgOiQNwxPJmk8P97UiB9WTnK8xrgXm5HF1QBknVAl8WH1bBA-5H1tAoeshbaDrQ-yQ6dw0JpR704cuI1_q_gpQAjfYLRA9mv_8_iOBKfcNoHWKPYSuWFA_rgFR5IJZQg_5DTpLcbV93sb4Fc3OT2fvinlw49PqkTdthmd351H18ez0w_x8srh8fzGfLSaW44ZMKOdOMkat94QSxgT3XDhec4mV8jWmxkpXW68sUdJbvgSuVENramXjsAd2VL3dedfDcgXOliWTafU6hZVJo44m6L87XbjSX-JGM6EaJWgRvLoTpHgzlA_Tq5AttK3pIA5ZEyaxYFxSUdCX_6DXcUhdWU8TIWtJm0bJQr3eUTbFnBP4_TAE69-h6hKq3oZa2Bf3p9-Tf1IswHQH3IYWxv-b9OXJ553yF6yUrT8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1674729987</pqid></control><display><type>article</type><title>Lifestyle intervention and/or statins for the reduction of C‐reactive protein in type 2 diabetes: From the look AHEAD study</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Belalcazar, L. Maria ; Haffner, Steven M. ; Lang, Wei ; Hoogeveen, Ron C. ; Rushing, Julia ; Schwenke, Dawn C. ; Tracy, Russell P. ; Pi‐Sunyer, F. Xavier ; Kriska, Andrea M. ; Ballantyne and the Look AHEAD (Action for Health in Diabetes) Research Group, Christie M.</creator><creatorcontrib>Belalcazar, L. Maria ; Haffner, Steven M. ; Lang, Wei ; Hoogeveen, Ron C. ; Rushing, Julia ; Schwenke, Dawn C. ; Tracy, Russell P. ; Pi‐Sunyer, F. Xavier ; Kriska, Andrea M. ; Ballantyne and the Look AHEAD (Action for Health in Diabetes) Research Group, Christie M. ; Look AHEAD (Action for Health in Diabetes) Research Group</creatorcontrib><description>Objective:
Cardiovascular risk remains high despite statin use. Overweight/obese diabetic persons usually have normal/low LDL‐cholesterol but high C‐reactive protein (CRP) levels. We aimed to examine the effects of intensive lifestyle intervention for weight loss (ILI) on CRP levels in overweight/obese diabetic individuals by statin use.
Design and Methods:
Look AHEAD was a randomized trial in overweight/obese type 2 diabetic individuals testing whether ILI would reduce cardiovascular mortality, when compared to usual care. CRP changes in 1,431 participants with biomarker levels, who remained on or off statin treatment for 1 year, were evaluated.
Results:
The reduction in CRP levels with ILI at 1 year in men and women on statins was −44.9 and −42.3%, respectively, compared to −13.7 and −21.0% for those on statins and usual care (P < 0.0001). At 1 year, median CRP levels were: 1.8 mg L−1 in participants randomized to ILI on statin therapy; 2.6 mg L−1 for those on statins randomized to usual care and 2.9 mg L−1 for participants not on statins but randomized to ILI. Weight loss was associated with 1‐year CRP reduction (P < 0.0001) in statin and nonstatin users.
Conclusions:
Our findings suggest that in overweight/obese diabetic persons, ILI and statin therapy may have substantial additive anti‐inflammatory benefits.</description><identifier>ISSN: 1930-7381</identifier><identifier>EISSN: 1930-739X</identifier><identifier>DOI: 10.1002/oby.20431</identifier><identifier>PMID: 23512860</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Aged ; C-Reactive Protein - metabolism ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - etiology ; Cardiovascular Diseases - prevention & control ; Cholesterol ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - therapy ; Diet ; Drug therapy ; Exercise ; Female ; Heart attacks ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Inflammation - drug therapy ; Inflammation - etiology ; Inflammation - therapy ; Life Style ; Male ; Middle Aged ; Obesity ; Obesity - blood ; Obesity - complications ; Obesity - therapy ; Statins ; Weight control ; Weight Loss - physiology ; Weight Reduction Programs</subject><ispartof>Obesity (Silver Spring, Md.), 2013-05, Vol.21 (5), p.944-950</ispartof><rights>Copyright © 2013 The Obesity Society</rights><rights>Copyright © 2013 The Obesity Society.</rights><rights>Copyright Blackwell Publishing Ltd. May 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5091-255d7332cff1213365f56d5457088f402ac7d4cf8c187fc5be5889242c79d0fe3</citedby><cites>FETCH-LOGICAL-c5091-255d7332cff1213365f56d5457088f402ac7d4cf8c187fc5be5889242c79d0fe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Foby.20431$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Foby.20431$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23512860$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Belalcazar, L. Maria</creatorcontrib><creatorcontrib>Haffner, Steven M.</creatorcontrib><creatorcontrib>Lang, Wei</creatorcontrib><creatorcontrib>Hoogeveen, Ron C.</creatorcontrib><creatorcontrib>Rushing, Julia</creatorcontrib><creatorcontrib>Schwenke, Dawn C.</creatorcontrib><creatorcontrib>Tracy, Russell P.</creatorcontrib><creatorcontrib>Pi‐Sunyer, F. Xavier</creatorcontrib><creatorcontrib>Kriska, Andrea M.</creatorcontrib><creatorcontrib>Ballantyne and the Look AHEAD (Action for Health in Diabetes) Research Group, Christie M.</creatorcontrib><creatorcontrib>Look AHEAD (Action for Health in Diabetes) Research Group</creatorcontrib><title>Lifestyle intervention and/or statins for the reduction of C‐reactive protein in type 2 diabetes: From the look AHEAD study</title><title>Obesity (Silver Spring, Md.)</title><addtitle>Obesity (Silver Spring)</addtitle><description>Objective:
Cardiovascular risk remains high despite statin use. Overweight/obese diabetic persons usually have normal/low LDL‐cholesterol but high C‐reactive protein (CRP) levels. We aimed to examine the effects of intensive lifestyle intervention for weight loss (ILI) on CRP levels in overweight/obese diabetic individuals by statin use.
Design and Methods:
Look AHEAD was a randomized trial in overweight/obese type 2 diabetic individuals testing whether ILI would reduce cardiovascular mortality, when compared to usual care. CRP changes in 1,431 participants with biomarker levels, who remained on or off statin treatment for 1 year, were evaluated.
Results:
The reduction in CRP levels with ILI at 1 year in men and women on statins was −44.9 and −42.3%, respectively, compared to −13.7 and −21.0% for those on statins and usual care (P < 0.0001). At 1 year, median CRP levels were: 1.8 mg L−1 in participants randomized to ILI on statin therapy; 2.6 mg L−1 for those on statins randomized to usual care and 2.9 mg L−1 for participants not on statins but randomized to ILI. Weight loss was associated with 1‐year CRP reduction (P < 0.0001) in statin and nonstatin users.
Conclusions:
Our findings suggest that in overweight/obese diabetic persons, ILI and statin therapy may have substantial additive anti‐inflammatory benefits.</description><subject>Aged</subject><subject>C-Reactive Protein - metabolism</subject><subject>Cardiovascular Diseases - blood</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Cholesterol</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - therapy</subject><subject>Diet</subject><subject>Drug therapy</subject><subject>Exercise</subject><subject>Female</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - etiology</subject><subject>Inflammation - therapy</subject><subject>Life Style</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Obesity</subject><subject>Obesity - blood</subject><subject>Obesity - complications</subject><subject>Obesity - therapy</subject><subject>Statins</subject><subject>Weight control</subject><subject>Weight Loss - physiology</subject><subject>Weight Reduction Programs</subject><issn>1930-7381</issn><issn>1930-739X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctuEzEUhkcIREthwQsgS2xgkcaX8WVYIKWhpZUidQMSrCzHPqYuk3Fqz6SaBRKPwDPyJJikRAWJlY91Pn86x39VPSf4mGBMp3E5HlNcM_KgOiQNwxPJmk8P97UiB9WTnK8xrgXm5HF1QBknVAl8WH1bBA-5H1tAoeshbaDrQ-yQ6dw0JpR704cuI1_q_gpQAjfYLRA9mv_8_iOBKfcNoHWKPYSuWFA_rgFR5IJZQg_5DTpLcbV93sb4Fc3OT2fvinlw49PqkTdthmd351H18ez0w_x8srh8fzGfLSaW44ZMKOdOMkat94QSxgT3XDhec4mV8jWmxkpXW68sUdJbvgSuVENramXjsAd2VL3dedfDcgXOliWTafU6hZVJo44m6L87XbjSX-JGM6EaJWgRvLoTpHgzlA_Tq5AttK3pIA5ZEyaxYFxSUdCX_6DXcUhdWU8TIWtJm0bJQr3eUTbFnBP4_TAE69-h6hKq3oZa2Bf3p9-Tf1IswHQH3IYWxv-b9OXJ553yF6yUrT8</recordid><startdate>201305</startdate><enddate>201305</enddate><creator>Belalcazar, L. Maria</creator><creator>Haffner, Steven M.</creator><creator>Lang, Wei</creator><creator>Hoogeveen, Ron C.</creator><creator>Rushing, Julia</creator><creator>Schwenke, Dawn C.</creator><creator>Tracy, Russell P.</creator><creator>Pi‐Sunyer, F. Xavier</creator><creator>Kriska, Andrea M.</creator><creator>Ballantyne and the Look AHEAD (Action for Health in Diabetes) Research Group, Christie M.</creator><general>John Wiley & Sons, Inc</general><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201305</creationdate><title>Lifestyle intervention and/or statins for the reduction of C‐reactive protein in type 2 diabetes: From the look AHEAD study</title><author>Belalcazar, L. Maria ; Haffner, Steven M. ; Lang, Wei ; Hoogeveen, Ron C. ; Rushing, Julia ; Schwenke, Dawn C. ; Tracy, Russell P. ; Pi‐Sunyer, F. Xavier ; Kriska, Andrea M. ; Ballantyne and the Look AHEAD (Action for Health in Diabetes) Research Group, Christie M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5091-255d7332cff1213365f56d5457088f402ac7d4cf8c187fc5be5889242c79d0fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>C-Reactive Protein - metabolism</topic><topic>Cardiovascular Diseases - blood</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Cholesterol</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - therapy</topic><topic>Diet</topic><topic>Drug therapy</topic><topic>Exercise</topic><topic>Female</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - etiology</topic><topic>Inflammation - therapy</topic><topic>Life Style</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Obesity</topic><topic>Obesity - blood</topic><topic>Obesity - complications</topic><topic>Obesity - therapy</topic><topic>Statins</topic><topic>Weight control</topic><topic>Weight Loss - physiology</topic><topic>Weight Reduction Programs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Belalcazar, L. Maria</creatorcontrib><creatorcontrib>Haffner, Steven M.</creatorcontrib><creatorcontrib>Lang, Wei</creatorcontrib><creatorcontrib>Hoogeveen, Ron C.</creatorcontrib><creatorcontrib>Rushing, Julia</creatorcontrib><creatorcontrib>Schwenke, Dawn C.</creatorcontrib><creatorcontrib>Tracy, Russell P.</creatorcontrib><creatorcontrib>Pi‐Sunyer, F. Xavier</creatorcontrib><creatorcontrib>Kriska, Andrea M.</creatorcontrib><creatorcontrib>Ballantyne and the Look AHEAD (Action for Health in Diabetes) Research Group, Christie M.</creatorcontrib><creatorcontrib>Look AHEAD (Action for Health in Diabetes) Research Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Obesity (Silver Spring, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Belalcazar, L. Maria</au><au>Haffner, Steven M.</au><au>Lang, Wei</au><au>Hoogeveen, Ron C.</au><au>Rushing, Julia</au><au>Schwenke, Dawn C.</au><au>Tracy, Russell P.</au><au>Pi‐Sunyer, F. Xavier</au><au>Kriska, Andrea M.</au><au>Ballantyne and the Look AHEAD (Action for Health in Diabetes) Research Group, Christie M.</au><aucorp>Look AHEAD (Action for Health in Diabetes) Research Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lifestyle intervention and/or statins for the reduction of C‐reactive protein in type 2 diabetes: From the look AHEAD study</atitle><jtitle>Obesity (Silver Spring, Md.)</jtitle><addtitle>Obesity (Silver Spring)</addtitle><date>2013-05</date><risdate>2013</risdate><volume>21</volume><issue>5</issue><spage>944</spage><epage>950</epage><pages>944-950</pages><issn>1930-7381</issn><eissn>1930-739X</eissn><abstract>Objective:
Cardiovascular risk remains high despite statin use. Overweight/obese diabetic persons usually have normal/low LDL‐cholesterol but high C‐reactive protein (CRP) levels. We aimed to examine the effects of intensive lifestyle intervention for weight loss (ILI) on CRP levels in overweight/obese diabetic individuals by statin use.
Design and Methods:
Look AHEAD was a randomized trial in overweight/obese type 2 diabetic individuals testing whether ILI would reduce cardiovascular mortality, when compared to usual care. CRP changes in 1,431 participants with biomarker levels, who remained on or off statin treatment for 1 year, were evaluated.
Results:
The reduction in CRP levels with ILI at 1 year in men and women on statins was −44.9 and −42.3%, respectively, compared to −13.7 and −21.0% for those on statins and usual care (P < 0.0001). At 1 year, median CRP levels were: 1.8 mg L−1 in participants randomized to ILI on statin therapy; 2.6 mg L−1 for those on statins randomized to usual care and 2.9 mg L−1 for participants not on statins but randomized to ILI. Weight loss was associated with 1‐year CRP reduction (P < 0.0001) in statin and nonstatin users.
Conclusions:
Our findings suggest that in overweight/obese diabetic persons, ILI and statin therapy may have substantial additive anti‐inflammatory benefits.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>23512860</pmid><doi>10.1002/oby.20431</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1930-7381 |
| ispartof | Obesity (Silver Spring, Md.), 2013-05, Vol.21 (5), p.944-950 |
| issn | 1930-7381 1930-739X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3689862 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged C-Reactive Protein - metabolism Cardiovascular Diseases - blood Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention & control Cholesterol Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - therapy Diet Drug therapy Exercise Female Heart attacks Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Inflammation - drug therapy Inflammation - etiology Inflammation - therapy Life Style Male Middle Aged Obesity Obesity - blood Obesity - complications Obesity - therapy Statins Weight control Weight Loss - physiology Weight Reduction Programs |
| title | Lifestyle intervention and/or statins for the reduction of C‐reactive protein in type 2 diabetes: From the look AHEAD study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T11%3A55%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lifestyle%20intervention%20and/or%20statins%20for%20the%20reduction%20of%20C%E2%80%90reactive%20protein%20in%20type%202%20diabetes:%20From%20the%20look%20AHEAD%20study&rft.jtitle=Obesity%20(Silver%20Spring,%20Md.)&rft.au=Belalcazar,%20L.%20Maria&rft.aucorp=Look%20AHEAD%20(Action%20for%20Health%20in%20Diabetes)%20Research%20Group&rft.date=2013-05&rft.volume=21&rft.issue=5&rft.spage=944&rft.epage=950&rft.pages=944-950&rft.issn=1930-7381&rft.eissn=1930-739X&rft_id=info:doi/10.1002/oby.20431&rft_dat=%3Cproquest_pubme%3E3661780501%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1674729987&rft_id=info:pmid/23512860&rfr_iscdi=true |